- Home
- OPFI vs SCPH Comparison
OPFI vs SCPH Comparison
Compare OPFI & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- SCPH
- Stock Information
- Founded
- OPFI 2009
- SCPH 2013
- Country
- OPFI United States
- SCPH United States
- Employees
- OPFI N/A
- SCPH N/A
- Industry
- OPFI Finance: Consumer Services
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- SCPH Health Care
- Exchange
- OPFI Nasdaq
- SCPH Nasdaq
- Market Cap
- OPFI 290.9M
- SCPH 160.6M
- IPO Year
- OPFI N/A
- SCPH 2017
- Fundamental
- Price
- OPFI $15.03
- SCPH $3.40
- Analyst Decision
- OPFI Buy
- SCPH Strong Buy
- Analyst Count
- OPFI 2
- SCPH 2
- Target Price
- OPFI $7.50
- SCPH $15.00
- AVG Volume (30 Days)
- OPFI 2.5M
- SCPH 251.3K
- Earning Date
- OPFI 03-06-2025
- SCPH 03-12-2025
- Dividend Yield
- OPFI 0.80%
- SCPH N/A
- EPS Growth
- OPFI 775.86
- SCPH N/A
- EPS
- OPFI 0.38
- SCPH N/A
- Revenue
- OPFI $260,661,000.00
- SCPH $30,278,000.00
- Revenue This Year
- OPFI N/A
- SCPH $173.14
- Revenue Next Year
- OPFI $6.51
- SCPH $131.01
- P/E Ratio
- OPFI $39.68
- SCPH N/A
- Revenue Growth
- OPFI 23.85
- SCPH 303.87
- 52 Week Low
- OPFI $2.35
- SCPH $3.08
- 52 Week High
- OPFI $15.13
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- OPFI 76.48
- SCPH 51.02
- Support Level
- OPFI $11.21
- SCPH $3.09
- Resistance Level
- OPFI $14.85
- SCPH $3.52
- Average True Range (ATR)
- OPFI 1.17
- SCPH 0.17
- MACD
- OPFI 0.17
- SCPH 0.01
- Stochastic Oscillator
- OPFI 77.48
- SCPH 69.32
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.